Key result
Forskolin reduced pulmonary pressures by >50% and increased stroke volume by ~70%, demonstrating a more pronounced hemodynamic effect than dobutamine and sodium nitroprusside.
Why the study?
Does forskolin improve hemodynamic parameters compared to dobutamine and sodium nitroprusside in patients with NYHA class III idiopathic congestive cardiomyopathy?
Population
12 patients with stage III (NYHA) idiopathic congestive cardiomyopathy
Comparison
Forskolin (HL 362) vs Dobutamine and sodium nitroprusside
Design
Cohort
Authors
Loading...
May support forskolin for acute hemodynamic support in severe HF; leaves open efficacy versus standard agents in randomized trials.
Does forskolin improve hemodynamic parameters compared to dobutamine and sodium nitroprusside in patients with NYHA class III idiopathic congestive cardiomyopathy?
Forskolin produces marked positive inotropic and vasodilatory effects in severe heart failure, potentially offering an advantage over catecholamines due to its receptor-independent mechanism.
Baumann et al. (1990) studied stage III (NYHA) congestive cardiomyopathy (n=12). Forskolin vs. Dobutamine and sodium nitroprusside was evaluated on Hemodynamic parameters (pulmonary pressures, cardiac output, stroke volume). Forskolin reduced pulmonary pressures by >50% and increased stroke volume by ~70%, demonstrating a more pronounced hemodynamic effect than dobutamine and sodium nitroprusside.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: